

## Corticotropin-releasing hormone and the blood-brain-barrier

Theoharis C. Theoharides<sup>1</sup> and Aphrodite D. Konstantinidou<sup>1,2</sup>

<sup>1</sup> Departments of Pharmacology and Experimental Therapeutics, Internal Medicine, Biochemistry and Psychiatry, Tufts University School of Medicine and Tufts-New England Medical Center, 136 Harrison Avenue, Boston, MA 02111, USA,

<sup>2</sup> Protypo Neurology Center, 79 Egnatias Street, Thessaloniki, 54635, Greece

### TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Mast cells and BBB regulation
4. Stress, CRH and inflammation
5. CRH and mast cells
6. Significance
7. Acknowledgments
8. References


## 1. ABSTRACT

Increased blood-brain-barrier (BBB) permeability precedes any clinical or pathologic signs and is critical in the pathogenesis of multiple sclerosis (MS) and brain metastases. CD4+ TH1 cells mediate demyelination in MS, but how they get sensitized and enter the brain to induce brain inflammation remains obscure. TH2 cytokines associated with allergic disorders have recently been implicated in MS, while genes upregulated in MS plaques include the mast cell-specific tryptase, the IgE receptor (Fc-epsilon-RI) and the histamine-1 receptor. Mast cell specific tryptase is elevated in the CSF of MS patients, induces microvascular leakage and stimulates protease-activated receptors (PAR), leading to widespread inflammation. BBB permeability, MS and brain metastases appear to worsen in response to acute stress that leads to the local release of corticotropin-releasing hormone (CRH), which activates brain mast cells to selectively release IL-6, IL-8 and vascular endothelial growth factor (VEGF). Acute stress increases BBB permeability that is dependent on CRH and mast cells. Acute stress shortens the time of onset of experimental allergic encephalomyelitis (EAE) that does not develop in W/W mast cell deficient or CRH -/- mice. Brain mast cell inhibition and CRHR antagonists offer novel therapeutic possibilities.

## 2. INTRODUCTION

The BBB is formed by a complex system of endothelial cells, astroglia, pericytes and perivascular mast cells (1), with tight junctions enclosed by a limiting basement membrane (2, 3). As a result, brain endothelial cells restrict passage of most circulating cells and molecules (4). However, BBB can play a dynamic role permitting certain peptides in and out of the brain (5). BBB breakdown (4) precedes any pathological or clinical signs of MS (6-8), as shown by trans-BBB leakage of albumin (9) and MRI-gadolinium studies (8). MS is a neurologic condition (10, 11) involving brain infiltration by lymphocytes that leads to demyelination (12, 13). Even though T cell involvement has been well documented in MS, recent evidence implicates also TH2 processes historically associated with allergic reactions (14-16). These findings have led to a "crucial re-appraisal of the CD-TH1 model for MS" that concluded that MS may be heterogeneous and not necessarily strictly autoimmune (17). The original proposal that brain mast cells may play a critical role (18) is now supported by numerous pieces of evidence.

Numerous studies have documented that the symptoms of MS can be precipitated by psychological



**Figure 1.** Electron photomicrograph of a “BBB unit” in a brain area with intense demyelination composed of a perivascular mast cell from a marmoset (*callithrix jacchus*) with EAE. A venule full of red blood cells (R) is shown. The endothelial cell (E) is surrounded by a pericyte (P), which in turn is tightly embraced by a mast cell (MC). Note intragranular activation with loss of electron dense material in many granules that appear empty (solid arrow) possibly containing lipid. Some secretory granules of mast cells are intact with homogeneous electron dense content (solid arrows against white background). R = red blood cell. E = nucleus of endothelial cell. P = nucleus of pericyte. MC = nucleus of mast cell. Reproduced with permission. Magnification: x 19,000

stress (19-25), including the appearance of new MRI lesions (26). In one study of parents with MS who had lost a child younger than 18 years (1980-1996 in Denmark) were matched to those who did not. The parents who lost a child unexpectedly had a significantly increased risk of MS more so than other bereaved parents (25). The fact that the function of peripheral blood leukocytes in MS patients is unaffected by stress is irrelevant as the effect of stress is on brain and not peripheral cells (27). In particular, it has been known that immunoglobulin free light chains can sensitize mast cell release of cytokines that induce T-cell mediated immune relations critical in MS (28). Moreover, mast cells can promote proliferation and T-cell activation, including TNF-alpha release, both through but also independent of IgE (29). Recent evidence, including one meta analysis, have now definitely linked acute stress to MS exacerbations (30). In one paper of 20 studies identified, 14 prospective studies were included and meta analysis showed a significantly increased risk of MS exacerbations after stressful events ( $p < 0.0001$ ) (30). These recent findings have prompted a review of the possible “stress-response systems for the pathogenesis and progression of MS,” but the hypotheses put forward of (a) the existence of glucocorticoid insensitive immune cells and (b) HPA axis hyperactivity fall short of explaining the processes involved in MS (31) since (a) the latter has never been shown and (b) should improve not worsen MS. In fact, there has not been any explanation of how this may occur until now. Clearly, the frequency, chronicity, severity and timing of stressors are important (32). Increased BBB permeability due to combat stress permitted entry into the


brain of pyridostigmine, an antidote given against organophosphate chemical warfare, to soldiers during the Gulf war leading to unexpected brain adverse effects. (37, 38) Restraint stress was also reported to increase mortality rates and lead to higher CNS viral load during Theiler’s virus infection (33). Stressed mice had increased inflammatory lesions in their spinal cord and developed autoimmune antibodies to myelin basic protein (MBP) (34).

Affected brain areas in MS fill with fibrotic tissue forming the MS plaque (26) that also contains activated mast cells (6, 35, 36). Mast cells have been associated with brain demyelination (39-41) (Figure 1). Gene array analysis recently showed that MS plaques overexpress genes for the IgE receptor (Fc-epsilon-RI), the histamine-1 receptor and the protease tryptase, all of which are associated with mast cells (42-44). Mast cell tryptase is elevated in the CSF of MS patients (45), can activate peripheral mononuclear cells to secrete TNF and IL-6 (46), as well as stimulate protease-activated receptors (PAR) to induce widespread inflammation (47, 48). Restraint stress resulted in activation of dura mast cells and CSF elevation of rat mast cell protease (49), effects abolished by polyclonal antiserum to CRH (49) and the CRHR-1 antagonist Antalarmin (49, 50). We showed that acute restraint stress shortens the time required for the development of experimental allergic encephalomyelitis (EAE) in mice and it increases BBB permeability (51). CRH  $-/-$  mice were recently shown to be resistant to EAE with decreased clinical disability and decreased brain infiltration by immune cells (52). Restraint stress induces mast cell dependent increase in mouse serum IL-6 (53), while examination stress dramatically increases serum TNF-alpha levels in medical student volunteers. (54) Moreover, virally induced encephalomyelitis could not develop in  $W/W^v$  mast cell deficient mice [WBBGF, (WB-W/+x C57BL/6- $W^v$  lineage)  $W/W^v$  mast cell deficient mice and their  $+/+$  normal counterparts (Jackson Laboratories, Bar Harbor, ME).] (55, 56), and EAE was attenuated and delayed in these mice (57).

The BBB is also defective in metastatic tumors permitting brain metastases (58). For instance, cancer cells can penetrate the BBB in metastatic melanoma (59) and mammary carcinoma (60). However, how the BBB permits tumor dissemination to the brain remains unknown (61). Brain metastases occur in about 30% of breast cancer patients, are associated with high morbidity and mortality (62) and are increased by stress (63, 64). Mast cell deficient mice were reported to have reduced metastases (65). Moreover, a mast cell stabilizer inhibited growth and metastases of rat mammary adenocarcinoma (66). Stress also increased susceptibility to UV-induced squamous cell carcinoma in a mouse model (67). Many AIDS patients develop neurologic problems that do not necessarily correlate with the viral load (68). One explanation may be that the HIV-1 virus does not infect peripheral neurons directly (69), but enters the brain through increased BBB permeability (70) inside macrophages and T-cells crossing the BBB.

### 3. BBB REGULATION AND MAST CELLS

The involvement of mast cells in BBB regulation was first hypothesized by us (18) and it was subsequently



**Figure 2.** Schematic representation of the hypothesis linking stress, CRH and mast cells to BBB permeability; NO = nitric oxide; VIP = vasoactive intestinal peptide; VEGF = vascular endothelial growth factor. Reproduced with permission.

further proposed that mast cell activation by CRH could explain how stress increases BBB permeability (Figure 2). This was confirmed using extravasation of <sup>99</sup>Tc-glucopate as a marker (50). Evidence that stress disrupts the BBB, possibly through mast cell mediators, had been published previously in rats (71-74). Increased BBB permeability due to forced swimming was shown in the cerebellum, thalamus and hypothalamus using Evans blue albumin or <sup>131</sup>I-sodium (72). Acute stress activates rat intracranial mast cells, an action blocked by pretreatment with CRH antiserum (49), and leads to increased BBB permeability (75), that is inhibited by the CRH-receptor-1 (CRHR-1) antagonist Antalarmin (50). Both acute stress and injection of CRH in the rat hypothalamus induce BBB permeability that is blocked by pretreatment with cromolyn and is absent in mast cell deficient W/W<sup>v</sup> mice (76). CRH, and the structurally related peptide urocortin (Ucn), also induce mast cell activation and vascular permeability in the skin (77). These effects, like those in the brain, are inhibited by cromolyn and Antalarmin and are absent in W/W<sup>v</sup> mice, implying a common mechanism in ectodermal tissues (76, 78, 79). We recently identified CRHR mRNA and protein in human leukemic mast (HMC-1) cells and human umbilical cord-derived cultured mast cells (hCBMCs) (80).


Mast cell involvement in BBB permeability is supported by reports that the mast cell secretagogue,

compound 48/80, stimulated brain mast cells in rats (81) and increased BBB permeability in pigeons (82). Moreover, local application of 48/80 to pia induced BBB permeability to fluorescein-labeled dextran (83). Using <sup>99m</sup>Tc-sodium pertechnetate or <sup>131</sup>I-serum albumin, histamine was shown to increase BBB permeability (84). This effect was blocked by the histamine-2 receptor antagonist cimetidine (84), which also blocked histamine-induced BBB permeability measured by trans-endothelial electrical resistance in brain microvessels (85). Brain histamine decreased in the hypothalamus of electrically stressed guinea pigs and in rats subjected to restraint stress (71), in which plasma histamine increased three-fold (86). Pretreatment with the mixed histamine/serotonin receptor antagonist cyproheptadine inhibited BBB permeability induced by forced swimming (72), suggesting that both histamine and serotonin may be involved in BBB permeability in rodents. Further evidence that histamine released under stress comes from mast cells was obtained when rats exposed to water immersion stress had a four-fold transient increase in plasma histamine levels that was absent in W/W<sup>v</sup> mast cell-deficient rats (87). We also showed that acute stress increases serum histamine and IL-6 levels, both of which are absent in mast cell deficient W/W<sup>v</sup> mice (53, 88).

In addition to histamine, tumor necrosis factor-alpha (TNF-alpha) may be involved in regulating BBB permeability (89). TNF-alpha was shown to be released along with histamine from rat hypothalamic mast cells (89) and was involved in both brain inflammation (90, 91) and BBB permeability (92). Other mast cell-derived vasodilatory molecules include tryptase, which can cause microvascular leakage (93), vascular endothelial growth factor (VEGF), an isoform of which is also vasodilatory (94) and vasoactive intestinal peptide (VIP) (95).

#### 4. STRESS, CRH AND INFLAMMATION

Chronic stress can suppress the immune system and influence human pathophysiology (96-100). Acute stress, however, can exacerbate inflammatory syndromes (101, 102), such as MS (18, 19, 21, 26) and migraines (102), both of which often co-exist in the same patients (103, 104). In fact, there is evidence that acute stress can stimulate the immune system. Stressed animals had greater leukocyte tissue infiltration, as well as TNF-alpha, and monocyte chemoattractant protein-1 (MCP-1) production (96, 99, 105-110). It is quite interesting that stress leads to increased serum IL-6 levels in care givers of chronically ill patients (111), but it is decreased in those who go to church regularly (112), indicating that reduction of stress could lead to decrease in a key pro-inflammatory cytokine. Corticotropin-releasing hormone (CRH) or factor (CRF) is a 41 amino acid peptide that regulates the hypothalamic-pituitary adrenal (HPA) axis (113) and coordinates the stress response through activation of the sympathetic nervous system (101). CRH acts through specific receptors (114, 115), which include CRHR-1 (116) and CRHR-2 (117). Both receptor types are located on brain neurons, but CRHR-2 has also been identified on cerebral arterioles



**Figure 3.** A mast cell (arrow) stained with toluidine blue adjacent to CRH positive nerve fibers around a blood vessel in the rat median eminence. Reproduced with permission. Magnification: x1,000

(118) that could be stimulated by CRH and Ucn directly (119). CRHR-2 has been further subdivided to CRHR-2alpha and CRHR-2beta (120) which are best activated by Ucn, a peptide with about 50% structural similarity to CRH (121). Two more forms of Ucn, Ucn II (122) and Ucn III (123) have also been identified and are potent CRHR-2 agonists. CRHR-2alpha was found exclusively in the brain of mice, while CRHR-2beta was also found outside the brain. Both CRH and CRH mRNA have been demonstrated in rodent spleen and thymus (124), while human peripheral blood leukocytes (125) and enterochromaffin cells (126) express mRNA for Ucn. CRH and CRHR mRNA exist in rodent and human skin (127-129), while CRH-like immunoreactivity is present in the dorsal horn of the spinal cord and dorsal root ganglia (130-132), as well as in sympathetic ganglia (132, 133). We showed that acute stress could increase the skin content of CRH (134). We also showed that human mast cells contain both CRH and Ucn that could be released in response to immunologic stimulation. (134) CRH stimulated leukocytes (124) to produce beta-endorphin, ACTH and alpha-melanocyte stimulating hormone (alpha-MSH), (18) as well as monocytes to secrete interleukin-1 (IL-1), and lymphocytes to produce IL-2 (135). CRH also stimulated lymphocyte proliferation (136, 137), increased IL-2 receptor expression on T-lymphocytes (136), was chemotactic for mononuclear leukocytes and activated CRHR-1 on spleen cells (138, 139).

### 5. CRH AND MAST CELLS

Mast cells derive from a bone marrow progenitor (140, 141) and mature in tissues depending on microenvironmental conditions (142). Mast cells are important for allergic reactions (142-145), but also immunity (146, 147), in autoimmunity and inflammation (102). Mature mast cells vary considerably (142) in their cytokine (148) and proteolytic enzyme content. However, the phenotypic expression of mast cells does not appear to be fixed (149, 150). Mast cells secrete various vasodilatory and proinflammatory mediators, such as histamine, heparin, kinins, proteases, (preformed) as well as leukotrienes,

prostaglandins, nitric oxide (NO), cytokines and VEGF (newly synthesized). In addition to IgE and antigen, anaphylatoxins, cytokines, hormones and neuropeptides can trigger mast cell secretion. The latter include SP (151), neuropeptide Y (NPY) (152), and nerve growth factor (NGF) (153). Brain mast cells do not normally express their surface growth factor (c-kit) receptor (154) or Fc-epsilon-RI (155), but do so in EAE (156). In such conditions, mast cells undergo ultrastructural alterations of their electron dense granular core indicative of secretion, but without degranulation, a process termed "activation" (81, 157, 158) "intragranular activation" (159) or "piecemeal" degranulation (160). This appearance was prominent in brain mast cells of non-human primates with EAE (161), and may be associated with the ability of mast cells to release some mediators selectively (162, 163), as shown for serotonin (164), eicosanoids (165-167) or IL-6 (168-170). Moreover, in certain diseases, such as scleroderma and interstitial cystitis, mast cells appear totally depleted of their granule content and they could not be recognized by light microscopy (phantom mast cells) (158, 171). The possible relationship of mast cells in stress-induced CNS pathophysiology is supported by findings that mast cell activation can occur in response to isolation stress (172), to restraint stress (49), to subordination stress, and during courtship following isolation of male doves (173). A functional association between mast cells and neurons has been reported (50) and the potential pathophysiological role of brain mast cells has been reviewed (102, 174, 175).

Mast cells are located perivascularly in close proximity to neurons (102, 130, 131, 159, 176-181) in the leptomeninges, (50) the choroid plexus, thalamus and hypothalamus, especially the median eminence in the rat (182-186), where 50% of histamine derives from mast cells (184, 187-189). The diencephalon is the brain area with the highest number of mast cells, (185) while the cerebellum also contains a smaller number. (190) Mast cells are localized around the cerebral microvasculature (191) and have been identified close to CRH positive neurons in the rat median eminence (49) (Figure 3). CRH administration in humans causes peripheral vasodilation and flushing reminiscent of mast cell activation (135, 192). Moreover, intradermal CRH administration leads to histamine-dependent swelling, (193) activation of mast cells (78) and Evans blue extravasation (78). It was also shown using iontophoresis and laser Doppler that CRH increased human skin vasodilation that was dependent on CRHR-1 and mast cells (194, 195). Moreover, CRHR-1 was shown to be involved in the stress-induced exacerbation of chronic contact dermatitis in rats (196). The involvement of CRH as a mediator of the cutaneous response to stress has been reviewed (197) and CRH has been shown to produce corticosteroids from melanocytes (198).

In addition to CRH stimulating mast cells, mast cell mediators could influence CRH release. For instance, human mast cells synthesize and secrete large amounts of CRH (199); histamine also increased CRH mRNA expression in the hypothalamus (200), and mast cells could stimulate the HPA axis (201-203). Moreover, CRH secretion could be triggered by IL-6 and IL-1 (168, 204-

208), both of which are released from mast cells (142, 209). Conversely, CRH stimulates IL-6 release (210-213). It is interesting that hyperthermic stress induced HPA axis activation and transiently increased IL-6 mRNA levels in the trigeminal ganglion (214). Moreover, restraint stress increased CRHR gene expression on the primary sensory nuclei of the trigeminal nerve suggesting that CRH could stimulate the nerve to secrete neuropeptides that could activate mast cells in parts of the brain innervated by the trigeminal nerve, such as the leptomeninges (215). Mast cells could also be activated by antidromic trigeminal (157) or cervical (216) ganglion stimulation, and SP reactive fibers were localized close to mast cells (50, 189, 217). Acute stress also increased BBB permeability in rats and mice only in brain areas containing mast cells (75).

We recently showed that normal human cultured mast cells express mRNA and protein for CRHR-1 and CRHR-2 (218). Stimulation of CRHR-1 led to selective release of VEGF (218), a process independent of extracellular calcium, but dependent on cAMP and p38 (219). Inflammatory triggers such as IL-1 and LPS were shown to upregulate CRHR-2 expression (220). A subpopulation of skin mast cells were shown to express CRHR (221) and such findings led to the premise that mast cells could serve as “sensors” in a “brain-skin” connection (222). The action of CRH on mast cells may not be direct. For instance, release of SP from sensory afferents could stimulate mast cell secretion *in vivo* (223). NT could be released from dorsal root ganglia (DRG) alone or together with CRH (80). A direct action of CRH on blood vessels cannot be precluded since CRHR-2 was identified on rat brain arterioles (120), CRH induced vasodilation of the fetal circulation (224), and both CRH and Ucn could stimulate cAMP production by brain endothelial cells (119). However, these effects on blood vessels may be delayed and could lead to either similar or opposite results to those of CRH stimulation of mast cells. Mast cells have also been activated by endothelin (225, 226), and blockade of the endothelin receptor was recently shown to block *in vivo* effects attributed to mast cells (227).

## 6. SIGNIFICANCE

Brain mast cells could increase BBB permeability and brain metastases by being the targets of CRH released locally by acute stress (Figure 1). Even though restraint stress does not represent psychological stress in humans, this animal model has been used (228, 229) for studies investigating the role of stress (97, 229-232). Moreover, 99-technetium gluceptate (<sup>99</sup>Tc), the marker used in our studies, has been used to assess BBB permeability in experimental gliomas (233) and in humans (234). Future studies could quantify entry of green fluorescent protein (GFP)-tagged T-cells administered following different periods of acute stress. (GFP)- tagged cells have been used to visualize metastatic cancers, including the brain (235-239).

The impact of our findings was highlighted in recent reviews on the versatile role of mast cells (240), as well as their potential as the next target for MS therapy

(241). Recent findings indicate that certain natural flavonoids can inhibit myelin phagocytosis by macrophages (242), as well as inhibiting EAE (239, 243). This is quite exciting as flavonoids have potent anti-inflammatory activity (244) and can block secretion of pro-inflammatory cytokines from human mast cells (245). In fact, certain dietary supplements combine such inhibitory substances (246) and could be used in clinical trials. Such flavonoids could also be combined with the heterocyclic antihistamine hydroxyzine, which we have recently shown in clinical trials to reduce MS disability (237, 247).

## 7. ACKNOWLEDGEMENTS

This work was supported in part by NIH grant R01 NS38326 and Theta Biomedical Consulting and Development Co., Inc. (Brookline, MA). Thanks are due to Ms. Jessica Christian for her patience and word processing skills. The use of brain mast cell blockers and CRHR antagonists for the treatment of brain inflammatory disorders is covered by US patents No. 5,250,529 (10/05/93) 5,821,259 (10/13/98), 5,855,884 (01/05/99), 6,689,748 (02/10/04) and 6,984,667 (01/10/06) awarded to TCT.

## 8. REFERENCES

1. Wahl M., A. Unterberg, A. Beathmann & L. Schilling. Mediators of blood-brain barrier dysfunction and formation of vasogenic brain edema. *J Cereb Blood Flow Metab* 8, 621-634 (1988)
2. de Boer A. G. & D. D. Breimer. Cytokines and blood-brain barrier permeability. *Prog Brain Res* 115, 425-451 (1998)
3. Petty M. A. & E. H. Lo. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. *Prog Neurobiol* 68, 311-323 (2002)
4. De Vreis H. E., J. Kuiper, A. G. de Boer, T. J. C. Van Berkel & D. D. Breimer. The blood-brain barrier in neuroinflammatory diseases. *Pharmacol Rev* 49, 143-155 (1997)
5. Kastin A. J., W. Pan, L. M. Maness & W. A. Banks. Peptides crossing the blood-brain barrier: some unusual observations. *Brain Res* 848, 96-100 (1999)
6. Kermode A. G., A. J. Thompson, P. Tofts, D. G. MacManus, B. E. Kendall, D. P. E. Kingsley, I. F. Moseley, P. Rudge & W. I. McDonald. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. *Brain* 113, 1477-1489 (1990)
7. Moor A. C. E., H. E. de Vries, A. G. de Boer & D. D. Breimer. The blood-brain barrier and multiple sclerosis. *Biochem Pharmacol* 47, 1717-1724 (1994)
8. Kwon E. E. & J. W. Prineas. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. *J Neuropathol Exp Neurol* 53, 625-636 (1994)
9. Syndulko K., W. W. Tourtellotte, A. J. Conrad, G. Izuierdo, Multiple Sclerosis Study Group & Alpha Interferon Study Group. Trans-blood-brain-barrier albumin leakage and comparisons of intrathecal IgG synthesis

- calculations in multiple sclerosis patients. *J Neuroimmunol* 46, 185-192 (1993)
10. Rodriguez M. Multiple sclerosis: insights into molecular pathogenesis and therapy. *Mayo Clin Proc* 72, 663-664 (1997)
11. Smith K. J. & W. I. McDonald. The pathophysiology of multiple sclerosis: The mechanisms underlying the production of symptoms and the natural history of the disease. *Philos Trans R Soc Lond B Biol Sci* 1390, 1649-1673 (1999)
12. Raine C. S. Multiple sclerosis: immune system molecule expression in the central nervous system. *J Neuropathol Exp Neurol* 53, 328-337 (1994)
13. McFarland H. F. Complexities in the treatment of autoimmune disease. *Science* 274, 2037-2038 (1996)
14. Robbie-Ryan M., M. B. Tanzola, V. H. Secor & M. A. Brown. Cutting edge: both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity. *J Immunol* 170, 1630-1634 (2003)
15. Pedotti R., J. J. De Voss, L. Steinman & S. J. Galli. Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. *Trends Immunol* 24, 479-484 (2003)
16. Pedotti R., J. J. DeVoss, S. Youssef, D. Mitchell, J. Wedemeyer, R. Madanat, H. Garren, P. Fontoura, M. Tsai, S. J. Galli, R. A. Sobel & L. Steinman. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. *Proc Natl Acad Sci USA* 100, 1867-1872 (2003)
17. McClellan K. & L. J. Scott. Tramadol/paracetamol. *Drugs* 63, 1079-1086 (2003)
18. Theoharides T. C. Mast cells: the immune gate to the brain. *Life Sci* 46, 607-617 (1990)
19. Goodin D. S., G. C. Ebers, K. P. Johnson, M. Rodriguez, W. A. Sibley & J. S. Wolinsky. The relationship of MS to physical trauma and psychological stress. *Neurology* 52, 1737-1745 (1999)
20. Warren S., S. Greenhill & K. G. Warren. Emotional stress and the development of multiple sclerosis: case control evidence of a relationship. *J Chronic Dis* 35, 821-831 (1982)
21. Mei-Tal V., S. Meyerowitz & G. L. Engel. The role of psychological process in a somatic disorder: multiple sclerosis. 1. The emotional setting of illness onset and exacerbation. *Psychosom Med* 32, 67-86 (1970)
22. Ackerman K. D., R. Heyman, B. S. Rabin, B. P. Anderson, P. R. Houck, E. Frank & A. Baum. Stressful life events precede exacerbations of multiple sclerosis. *Psychosom Med* 64, 916-920 (2002)
23. Ackerman K. D., A. Stover, R. Heyman, B. P. Anderson, P. R. Houck, E. Frank, B. S. Rabin & A. Baum. Robert Ader New Investigator award. Relationship of cardiovascular reactivity, stressful life events, and multiple sclerosis disease activity. *Brain Behav Immun* 17, 141-151 (2003)
24. Buljevac D., W. C. Hop, W. Reedeker, A. C. Janssens, F. G. van der Meche, P. van Doorn & R. Q. Hintzen. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. *BMJ* 327, 646 (2003)
25. Li J., C. Johansen, H. Bronnum-Hansen, E. Stenager, N. Koch-Henriksen & J. Olsen. The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark. *Neurology* 62, 726-729 (2004)
26. Mohr D. C., D. E. Goodkin, P. Bacchetti, A. C. Boudewyn, L. Huang, P. Marrietta, W. Cheuk & B. Dee. Psychological stress and the subsequent appearances of new brain MRI lesions in MS. *Neurology* 55, 55-61 (2000)
27. Heesen C., H. Schulz, M. Schmidt, S. Gold, W. Tessler & K. H. Schulz. Endocrine and cytokine responses to acute psychological stress in multiple sclerosis. *Brain Behav Immun* 16, 282-287 (2002)
28. Redegeld F. A. & F. P. Nijkamp. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? *Trends Immunol* 24, 181-185 (2005)
29. Nakae S., H. Suto, M. Kakurai, J. D. Sedgwick, M. Tsai & S. J. Galli. Mast cells enhance T cell activation: Importance of mast cell-derived TNF. *Proc Natl Acad Sci U S A* 102, 6467-6472 (2005)
30. Mohr D. C., S. L. Hart, L. Julian, D. Cox & D. Pelletier. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. *BMJ* 328, 731 (2004)
31. Gold S. M., D. C. Mohr, I. Huitinga, P. Flachenecker, E. M. Sternberg & C. Heesen. The role of stress-response systems for the pathogenesis and progression of MS. *Trends Immunol* 26, 644-652 (2005)
32. Brown R. F., C. C. Tennant, S. M. Dunn & J. D. Pollard. A review of stress-relapse interactions in multiple sclerosis: important features and stress-mediating and -moderating variables. *Mult Scler* 11, 477-484 (2005)
33. Campbell T., M. W. Meagher, A. Sieve, B. Scott, R. Storts, T. H. Welsh & C. J. Welsh. The effects of restraint stress on the neuropathogenesis of Theiler's virus infection: I. Acute disease. *Brain Behav Immun* 15, 235-254 (2001)
34. Sieve A. N., A. J. Steelman, C. R. Young, R. Storts, T. H. Welsh, C. J. Welsh & M. W. Meagher. Chronic restraint stress during early Theiler's virus infection exacerbates the subsequent demyelinating disease in SJL mice. *J Neuroimmunol* 155, 103-118 (2004)
35. Olsson Y. Mast cells in plaques of multiple sclerosis. *Acta Neurol Scand* 50, 611-618 (1974)
36. Krüger P. G., L. Bo, K. M. Myhr, A. E. Karlsen, A. Taale, H. I. Nyland & S. Mork. Mast cells and multiple sclerosis: a light and electron microscopic study of mast cells in multiple sclerosis emphasizing staining procedures. *Acta Neurol Scand* 81, 31-36 (1990)
37. Hanin I. The Gulf War, stress and a leaky blood-brain barrier. *Nat Med* 2, 1307-1308 (1996)
38. Friedman A., D. Kaufer, J. Shemer, I. Hendler, H. Soreq & I. Tur-Kaspa. Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. *Nat Med* 2, 1382-1385 (1996)
39. Dietsch G. N. & D. J. Hinrichs. The role of mast cells in the elicitation of experimental allergic encephalomyelitis. *J Immunol* 142, 1476-1481 (1989)
40. Johnson D., P. A. Seeldrayers & H. L. Weiner. The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P<sub>2</sub> can stimulate mast cell degranulation. *Brain Res* 444, 195-198 (1988)
41. Theoharides T. C., V. Dimitriadou, R. J. Letourneau, J. J. Rozniecki, H. Vliagoftis & W. S. Boucher. Synergistic

- action of estradiol and myelin basic protein on mast cell secretion and brain demyelination: changes resembling early stages of demyelination. *Neuroscience* 57, 861-871 (1993)
42. Lock C., G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. Langer-Gould, S. Strober, B. Cannella, J. Allard, P. Klonowski, A. Austin, N. Lad, N. Kaminski, S. J. Galli, J. R. Oksenberg, C. S. Raine, R. Heller & L. Steinman. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. *Nat Med* 8, 500-508 (2002)
43. Bomprezzi R., M. Ringner, S. Kim, M. L. Bittner, J. Khan, Y. Chen, A. Elkahloun, A. Yu, B. Bielekova, P. S. Meltzer, R. Martin, H. F. McFarland & J. M. Trent. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. *Hum Mol Genet* 12, 2191-2199 (2003)
44. De Jager P. L. & D. A. Hafler. Gene expression profiling in MS: what is the clinical relevance? *Lancet Neurol* 3, 269 (2004)
45. Rozniecki J. J., S. L. Hauser, M. Stein, R. Lincoln & T. C. Theoharides. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. *Ann Neurol* 37, 63-66 (1995)
46. Malamud V., A. Vaaknin, O. Abramsky, M. Mor, L. E. Burgess, A. Ben-Yehudah & H. Lorberboum-Galski. Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-alpha, IL-6 and IL-1 beta: possible relevance to multiple sclerosis. *J Neuroimmunol* 138, 115-122 (2003)
47. Molino M., E. S. Barnathan, R. Numerof, J. Clark, M. Dreyer, A. Cumashi, J. A. Hoxie, N. Schechter, M. Woolkalis & L. F. Brass. Interactions of mast cell tryptase with thrombin receptors and PAR-2. *J Biol Chem* 272, 4043-4049 (1997)
48. Schechter N. M., L. F. Brass, R. M. Lavker & P. J. Jensen. Reaction of mast cell proteases tryptase and chymase with protease activated receptors (PARs) on keratinocytes and fibroblasts. *J Cell Physiol* 176, 365-373 (1998)
49. Theoharides T. C., C. P. Spanos, X. Pang, L. Alferes, K. Ligris, R. Letourneau, J. J. Rozniecki, E. Webster & G. Chrousos. Stress-induced intracranial mast cell degranulation. A corticotropin releasing hormone-mediated effect. *Endocrinology* 136, 5745-5750 (1995)
50. Rozniecki J. J., V. Dimitriadou, M. Lambracht-Hall, X. Pang & T. C. Theoharides. Morphological and functional demonstration of rat dura mast cell-neuron interactions *in vitro* and *in vivo*. *Brain Res* 849, 1-15 (1999)
51. Chandler N., S. Jacobson, R. Connolly, P. Esposito & T. C. Theoharides. Acute stress shortens the time of onset of experimental allergic encephalomyelitis (EAE) in SJL/J mice. *Brain Behav Immun* 16, 757-763 (2002)
52. Benou C., Y. Wang, J. Imitola, L. VanVlerken, C. Chandras, K. P. Karalis & S. J. Khoury. Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis. *J Immunol* 174, 5407-5413 (2005)
53. Huang M., X. Pang, K. Karalis & T. C. Theoharides. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. *Cardiovasc Res* 59, 241-249 (2003)
54. Lalive P. H., P. R. Burkhard & M. Chofflon. TNF-alpha and psychologically stressful events in healthy subjects: potential relevance for multiple sclerosis relapse. *Behav Neurosci* 116, 1093-1097 (2002)
55. Griffin D. E. & Q. P. Mendoza. Identification of the inflammatory cells present in the central nervous system of normal and mast cell-deficient mice during Sindbis virus encephalitis. *Cell Immunol* 97, 454-459 (1986)
56. Mokhtarian F. & D. E. Griffin. The role of mast cells in virus-induced inflammation in the murine central nervous system. *Cell Immunol* 86, 491-500 (1984)
57. Secor V. H., W. E. Secor, C.-A. Gutekunst & M. A. Brown. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. *J Exp Med* 191, 813-821 (2000)
58. Menter D. G., J. L. Herrmann & G. L. Nicolson. The role of trophic factors and autocrine/paracrine growth factors in brain metastasis. *Clin Exp Metastasis* 13, 67-88 (1995)
59. Hasegawa H., Y. Ushio, T. Hayakawa, K. Yamada & H. Mogami. Changes of the blood-brain barrier in experimental metastatic brain tumors. *J Neurosurg* 59, 304-310 (1983)
60. Boogerd W. Central nervous system metastasis in breast cancer. *Radiother Oncol* 40, 5-22 (1996)
61. Weber G. F. & S. Ashkar. Molecular mechanisms of tumor dissemination in primary and metastatic brain cancers. *Brain Res Bull* 53, 421-424 (2000)
62. Lassman A. B. & L. M. DeAngelis. Brain metastases. *Neurol Clin* 21, 1-23 (2003)
63. Ben-Eliyahu S., R. Yirmiya, J. C. Liebeskind, A. N. Taylor & R. P. Gale. Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. *Brain Behav Immun* 5, 193-205 (1991)
64. Nishizuka I., T. Ishikawa, Y. Hamaguchi, M. Kamiyama, Y. Ichikawa, K. Kadota, R. Miki, Y. Tomaru, N. Tominaga, Y. Mizuno, H. Goto, R. Yano, H. Nitanda, S. Togo, Y. Okazaki, Y. Hayashizaki & H. Shimada. Analysis of gene expression involved in brain metastasis from breast cancer using cDNA microarray. *Breast Cancer* 9, 26-32 (2002)
65. Starkey J. R., P. K. Crowle & S. Taubenberger. Mast-cell-deficient W/W<sup>v</sup> mice exhibit a decreased rate of tumor angiogenesis. *Int J Cancer* 42, 48-52 (1988)
66. Dabbous M. K., L. Haney, G. L. Nicolson, D. Eckley & D. E. Woolley. Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF. *Br J Cancer* 63, 873-878 (1991)
67. Saul A. N., T. M. Oberyshyn, C. Daugherty, D. Kusewitt, S. Jones, S. Jewell, W. B. Malarkey, A. Lehman, S. Lemeshow & F. S. Dhabhar. Chronic stress and susceptibility to skin cancer. *J Natl Cancer Inst* 97, 1760-1767 (2005)
68. Perry S. & R. F. Marotta. AIDS dementia: a review of the literature. *Alzheimer Dis Assoc Disord* 1, 221-235 (1987)
69. Gelbard H. A. & L. G. Epstein. HIV-1 encephalopathy in children. *Curr Opin Pediatr* 7, 655-662 (1995)
70. Gray F., H. Adle-Biassette, F. Brion, T. Ereau, I. le Maner, V. Levy & G. Corcket. Neuronal apoptosis in human immunodeficiency virus infection. *J Neurovirol* 6, S38-S43 (2000)

71. Belova I. & G. Jonsson. Blood-brain barrier permeability and immobilization stress. *Acta Physiol Scand* 116, 21-29 (1982)
72. Sharma H. S., J. Cervos-Navarro & P. K. Dey. Increased blood-brain barrier permeability following acute short-term swimming exercise in conscious normotensive young rats. *Neuroscience Res* 10, 211-221 (1991)
73. Skultetyova I., D. Tokarev & D. Jezova. Stress-induced increase in blood-brain barrier permeability in control and monosodium glutamate-treated rats. *Brain Res Bull* 45, 175-178 (1998)
74. Sharma H. S., J. Westman, J. C. Navarro, P. K. Dey & F. Nyberg. Probable involvement of serotonin in the increased permeability of the blood-brain barrier by forced swimming. An experimental study using Evans blue and <sup>131</sup>I-sodium tracers in the rat. *Behav Brain Res* 72, 189-196 (1995)
75. Esposito P., D. Gheorghe, K. Kandere, X. Pang, R. Conally, S. Jacobson & T. C. Theoharides. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. *Brain Res* 888, 117-127 (2001)
76. Esposito P., N. Chandler, K. Kandere-Grzybowska, S. Basu, S. Jacobson, R. Connolly, D. Tutor & T. C. Theoharides. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. *J Pharmacol Exp Ther* 303, 1061-1066 (2002)
77. Singh L. K., X. Pang, N. Alexacos, R. Letourneau & T. C. Theoharides. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin and substance P: A link to neurogenic skin disorders. *Brain Behav Immunity* 13, 225-239 (1999)
78. Theoharides T. C., L. K. Singh, W. Boucher, X. Pang, R. Letourneau, E. Webster & G. Chrousos. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. *Endocrinology* 139, 403-413 (1998)
79. Singh L. K., W. Boucher, X. Pang, R. Letourneau, D. Seretakis, M. Green & T. C. Theoharides. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of CRH receptors. *J Pharmacol Exp Ther* 288, 1349-1356 (1999)
80. Theoharides T. C., J. M. Donelan, N. Papadopoulou, J. Cao, D. Kempuraj & P. Conti. Mast cells as targets of corticotropin-releasing factor and related peptides. *Trends Pharmacol Sci* 25, 563-568 (2004)
81. Dimitriadou V., M. Lambracht-Hall, J. Reichler & T. C. Theoharides. Histochemical and ultrastructural characteristics of rat brain perivascular mast cells stimulated with compound 48/80 and carbachol. *Neuroscience* 39, 209-224 (1990)
82. Zhuang X., A.-J. Silverman & R. Silver. Brain mast cell degranulation regulates blood-brain barrier. *J Neurobiol* 31, 393-403 (1996)
83. Mayhan W. G. Leukocyte adherence contributes to disruption of the blood-brain barrier during activation of mast cells. *Brain Res* 869, 112-120 (2000)
84. Boertje S. R., D. Le Beau & C. Williams. Blockade of histamine-stimulated alterations in cerebrovascular permeability by the H2-receptor antagonist cimetidine. *Neuropharmacology* 28, 749-752 (1989)
85. Butt A. M. & H. C. Jones. Effect of histamine and antagonists on electrical resistance across the blood-brain-barrier in rat brain-surface microvessels. *Brain Res* 569, 100-105 (1992)
86. Huang Z., T. Mochizuki, H. Watanabe & K. Maeyama. Histamine release induced by immobilization, gentle handling and decapitation from mast cells and its inhibition by nedocromil in rats. *Jpn J Pharmacol* 80, 255-262 (1999)
87. Huang Z., T. Mochizuki, H. Watanabe, M. Kagoshima & K. Maeyama. Biphasic evaluation of plasma histamine induced by water immersion stress, and their sources in rats. *Eur J Pharmacol* 360, 139-146 (1998)
88. Huang M., X. Pang, L. Letourneau, W. Boucher & T. C. Theoharides. Acute stress induces cardiac mast cell activation and histamine release, effects that are increased in apolipoprotein E knockout mice. *Cardiovasc Res* 55, 150-160 (2002)
89. Cocchiara R., A. Bongiovanni, G. Albeggiani, A. Azzolina & D. Geraci. Evidence that brain mast cells can modulate neuroinflammatory responses by tumor necrosis factor- $\alpha$  production. *Neuroreport* 9, 95-98 (1998)
90. Probert L., K. Akassoglou, G. Kassiotis, M. Pasparakis, L. Alexopoulou & G. Kollias. TNF- $\alpha$  transgenic and knockout models of CNS inflammation and degeneration. *J Neuroimmunol* 72, 137-141 (1997)
91. Klinkert W. E. F., K. Kojima, W. Lesslauer, W. Rinner, H. Lassmann & H. Wekerle. TNF- $\alpha$  receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: An overview. *J Neuroimmunol* 72, 163-168 (1997)
92. Kim K. S., C. A. Wass, A. S. Cross & S. M. Opal. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. *Lymphokine Cytokine Res* 11, 293-298 (1992)
93. He S. & A. F. Walls. Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. *Eur J Pharmacol* 328, 89-97 (1997)
94. Grutzkau A., S. Kruger-Krasagakes, H. Baumeister, C. Schwarz, H. Kogel, P. Welker, U. Lippert, B. M. Henz & A. Moller. Synthesis, storage and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: Implications for the biological significance of VEGF<sub>206</sub>. *Mol Biol Cell* 9, 875-884 (1998)
95. Lutz E., W. Chan, N. S. Track, A. Goth & S. I. Said. Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. *Nature* 275, 661-662 (1978)
96. Dhabhar F. S. & B. S. McEwen. Enhancing versus suppressive effects of stress hormones on skin immune function. *Proc Natl Acad Sci USA* 96, 1059-1064 (1999)
97. Khansari D. N., A. J. Murgu & R. E. Faith. Effects of stress on the immune system. *Immunol Today* 11, 170-175 (1990)
98. Kort W. J. The effect of chronic stress on the immune response. *Adv Neuroimmunol* 4, 1-11 (1994)
99. Rinner I., K. Schauenstein, H. Mangge, S. Porta & R. Kvetnansky. Opposite effects of mild and severe stress on in vitro activation of rat peripheral blood lymphocytes. *Brain Behav Immunol* 6, 130-140 (1992)
100. Elenkov I. J., E. L. Webster, D. J. Torpy & G. P. Chrousos. Stress, corticotropin-releasing hormone,



- glucocorticoids, and the immune/inflammatory response: acute and chronic effects. *Ann NY Acad Sci* 876, 1-11 (1999)
101. Sternberg E. M., G. P. Chrousos, R. L. Wilder & P. W. Gold. The stress response and the regulation of inflammatory disease. *Ann Intern Med* 117, 854-866 (1992)
102. Theoharides T. C. Mast cell: a neuroimmunoendocrine master player. *Int J Tissue React* 18, 1-21 (1996)
103. Watkins S. M. & M. Espir. Migraine and multiple sclerosis. *J Neurol Neurosurg Psychiatry* 32, 35-37 (1969)
104. Freedman M. S. & T. A. Gray. Vascular headache: a presenting symptom of multiple sclerosis. *Can J Neurol Sci* 16, 63-66 (1989)
105. Viswanathan K., C. Daugherty & F. S. Dhabhar. Stress as an endogenous adjuvant: augmentation of the immunization phase of cell-mediated immunity. *Int Immunol* 17, 1059-1069 (2005)
106. Dhabhar F. S., A. H. Miller, B. S. McEwen & R. L. Spencer. Effects of stress on immune cell distribution: dynamics and hormonal mechanisms. *J Immunol* 154, 5511-5527 (1995)
107. Dhabhar F. & B. S. McEwen. Stress-induced enhancement of antigen-specific cell-mediated immunity. *J Immunol* 156, 2608-2615 (1996)
108. Wood P. G., M. H. Karol, A. W. Kusnecov & B. S. Rabin. Enhancement of antigen-specific humoral and cell-mediated immunity by electric footshock stress in rats. *Brain Behav Immun* 7, 121-134 (1993)
109. Lysle D. T., J. E. Cunnick & B. S. Rabin. Stressor-induced alteration of lymphocyte proliferation in mice: evidence for enhancement of mitogenic responsiveness. *Brain Behav Immun* 4, 269-277 (1990)
110. Millar D. B., J. R. Thomas, N. D. Pacheco & F. M. Rollwagen. Natural killer cell cytotoxicity and T-cell proliferation is enhanced by avoidance behavior. *Brain Behav Immun* 7, 144-153 (1993)
111. Kiecolt-Glaser J. K., K. J. Preacher, R. C. MacCallum, C. Atkinson, W. B. Malarkey & R. Glaser. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. *Proc Natl Acad Sci USA* 100, 9090-9095 (2003)
112. Lutgendorf S. K., D. Russell, P. Ullrich, T. B. Harris & R. Wallace. Religious participation, interleukin-6, and mortality in older adults. *Health Psychol* 23, 465-475 (2004)
113. Chrousos G. P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. *N Engl J Med* 332, 1351-1362 (1995)
114. Chalmers D. T., T. W. Lovenberg, D. E. Grigoriadis, D. P. Behan & E. B. DeSouza. Corticotropin-releasing factor receptors: from molecular biology to drug design. *Trends Pharmacol Sci* 17, 166-172 (1996)
115. Dieterich K. D., H. Lehnert & E. B. De Souza. Corticotropin-releasing factor receptors: an overview. *Exp Clin Endocrinol Diabetes* 105, 65-82 (1997)
116. Chen R., K. A. Lewis, M. H. Perrin & W. W. Vale. Expression cloning of a human corticotropin-releasing factor receptor. *Proc Natl Acad Sci USA* 90, 8967-8971 (1993)
117. Lovenberg T. W., C. W. Liaw, D. E. Grigoriadis, W. Clevenger, D. T. Chalmers, E. B. DeSouza & T. Oltersdorf. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. *Proc Natl Acad Sci USA* 92, 836-840 (1995)
118. Chalmers D. T., T. W. Lovenberg & E. B. DeSouza. Localization of novel corticotropin-releasing factor receptor (CRF<sub>2</sub>) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF<sub>1</sub> receptor mRNA expression. *J Neurosci* 10, 6340-6350 (1995)
119. Esposito P., S. Basu, R. Letourneau, S. Jacobson & T. C. Theoharides. Corticotropin-releasing factor (CRF) can directly affect brain microvessel endothelial cells. *Brain Res* 968, 192-198 (2003)
120. Lovenberg T. W., D. T. Chalmers, C. Liu & E. B. DeSouza. CRF<sub>2alpha</sub> and CRF<sub>2beta</sub> receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. *Endocrinol* 136, 4139-4142 (1995)
121. Vaughan J., C. Donaldson, J. Bittencourt, M. H. Perrin, K. Lewis, S. Sutton, R. Chan, A. V. Turnbull, D. Lovejoy, C. Rivier, J. Rivier, P. E. Sawchenko & W. Vale. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. *Nature* 378, 287-292 (1995)
122. Million M., C. Maillot, P. Saunders, J. Rivier, W. Vale & Y. Taché. Human urocortin II, a new CRF related peptide, displays selective CRF<sub>2</sub>-mediated action on gastric transit in rats. *Am J Physiol Gastrointest Liver Physiol* 282, G34-G40 (2002)
123. Lewis K., C. Li, M. H. Perrin, A. Blount, K. Kunitake, C. Donaldson, J. Vaughan, T. M. Reyes, J. Gulyas, W. Fischer, L. Bilezikjian, J. Rivier, P. E. Sawchenko & W. W. Vale. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF 2 receptor. *Proc Natl Acad Sci USA* 98, 7570-7575 (2001)
124. Karalis K., J. M. Louis, D. Bae, H. Hilderbrand & J. A. Majzoub. CRH and the immune system. *J Neuroimmunol* 72, 131-136 (1997)
125. Bamberger C. M., M. Wald, A.-M. Bamberger, S. Ergun, F. U. Beil & H. M. Schulte. Human lymphocytes produce urocortin, but not corticotropin-releasing hormone. *J Clin Endocrinol Metab* 83, 708-711 (1998)
126. Kawahito Y., H. Sano, M. Kawata, K. Yuri, S. Mukai, Y. Yamamura, H. Kato, G. P. Chrousos, R. L. Wilder & M. Kondo. Local secretion of corticotropin-releasing hormone by enterochromaffin cells in human colon. *Gastroenterol* 106, 859-865 (1994)
127. Slominski A., G. Ermak, J. Hwang, A. Chakraborty, J. E. Mazurkiewicz & M. Mihm. Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin. *FEBS Lett* 374, 113-116 (1995)
128. Roloff B., K. Fechner, A. Slominski, J. Furkert, V. A. Botchkarev, S. Bulfone-Paus, J. Zipper, E. Krause & R. Paus. Hair cycle-dependent expression of corticotropin-releasing factor (CRF) and CRF receptors in murine skin. *FASEB J* 12, 287-297 (1998)
129. Slominski A., G. Ermak, J. Hwang, J. Mazurkiewicz, D. Corliss & A. Eastman. The expression of proopiomelanocortin (POMC) and of corticotropin releasing hormone receptor (CRH-R) genes in mouse skin. *Biochim Biophys Acta* 1289, 247-251 (1996)

130. Skofitsch G., J. M. Savitt & D. M. Jacobowitz. Suggestive evidence for a functional unit between mast cells and substance P fibers in the rat diaphragm and mesentery. *Histochemistry* 82, 5-8 (1985)
131. Skofitsch G., N. Zamir, C. J. Helke, J. M. Savitt & D. M. Jacobowitz. Corticotropin-releasing factor-like immunoreactivity in sensory ganglia and capsaicin sensitive neurons of the rat central nervous system: colocalization with other neuropeptides. *Peptides* 6, 307-318 (1985)
132. Merchenthaler I., M. A. Hynes, S. Vingh, A. V. Schally & P. Petrusz. Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat spinal cord. *Brain Res* 275, 373-377 (1983)
133. Suda T., N. Tomori, F. Tozawa, T. Mouri, H. Demura & K. Shizume. Distribution and characterization of immunoreactive corticotropin-releasing factor in human tissues. *J Clin Endocrinol Metab* 59, 861-866 (1984)
134. Lytinas M., D. Kempuraj, M. Huang, W. Boucher, P. Esposito & T. C. Theoharides. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. *Int Arch Allergy Immunol* 130, 224-231 (2003)
135. Singh V. K. & C. S. J. Leu. Enhancing effect of corticotropin-releasing neurohormone on the production of interleukin-1 and interleukin-2. *Neurosci Lett* 120, 151-154 (1990)
136. Singh V. K. Stimulatory effect of corticotropin-releasing neurohormone on human lymphocyte proliferation and interleukin-2 receptor expression. *J Neuroimmunol* 23, 256-262 (1989)
137. McGillis J. P., A. Park, P. Rubin-Fletcher, C. Turck, M. F. Dallman & D. G. Payan. Stimulation of rat B-lymphocyte proliferation by corticotropin-releasing factor. *J Neurosci Res* 23, 346-352 (1989)
138. Radulovic M., F. M. Dautzenberg, S. Sydow, J. Radulovic & J. Spiess. Corticotropin-releasing factor receptor 1 in mouse spleen: Expression after immune stimulation and identification of receptor-bearing cells. *J Immunol* 162, 3013-3021 (1999)
139. Poliak S., F. Mor, P. Conlon, T. Wong, N. Ling, J. Rivier, W. Vale & L. Steinman. Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. *J Immunol* 158, 5751-5756 (1997)
140. Rodewald H. R., M. Dessing, A. M. Dvorak & S. J. Galli. Identification of a committed precursor for the mast cell lineage. *Science* 271, 818-822 (1996)
141. Chen C. C., M. A. Grimbaldeston, M. Tsai, I. L. Weissman & S. J. Galli. Identification of mast cell progenitors in adult mice. *Proc Natl Acad Sci U S A* 102, 11408-11413 (2005)
142. Galli S. J. New concepts about the mast cell. *N Engl J Med* 328, 257-265 (1993)
143. Siraganian R. P. Mast cell signal transduction from the high-affinity IgE receptor. *Curr Opin Immunol* 15, 639-646 (2003)
144. Blank U. & J. Rivera. The ins and outs of IgE-dependent mast-cell exocytosis. *Trends Immunol* 25, 266-273 (2004)
145. Kraft S., S. Rana, M. H. Jouvin & J. P. Kinet. The role of the Fc-epsilon-R1 beta-chain in allergic diseases. *Int Arch Allergy Immunol* 135, 62-72 (2004)
146. Galli S. J., S. Nakae & M. Tsai. Mast cells in the development of adaptive immune responses. *Nat Immunol* 6, 135-142 (2005)
147. Galli S. J., J. Kalesnikoff, M. A. Grimbaldeston, A. M. Piliponsky, C. M. Williams & M. Tsai. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. *Annu Rev Immunol* 23, 749-786 (2005)
148. Bradding P., Y. Okayama, P. H. Howarth, M. K. Church & S. T. Holgate. Heterogeneity of human mast cells based on cytokine content. *J Immunol* 155, 297-307 (1995)
149. Levi-Schaffer F., K. F. Austen, P. M. Gravallesse & R. L. Stevens. Co-culture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. *Proc Natl Acad Sci USA* 83, 6485-6488 (1986)
150. Bischoff S. C., G. Sellge, A. Lorentz, W. Sebald, R. Raab & M. P. Manns. IL-4 enhances proliferation and mediator release in mature human mast cells. *Proc Natl Acad Sci USA* 96, 8080-8085 (1999)
151. Matsuda H., K. Kawakita, Y. Kiso, T. Nakano & Y. Kitamura. Substance P induces granulocyte infiltration through degranulation of mast cells. *J Immunol* 142, 927-931 (1989)
152. Carraway R., D. E. Cochrane, J. B. Lansman, S. E. Leeman, B. M. Paterson & H. J. Welch. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. *J Physiol* 323, 403-414 (1982)
153. Tal M. & R. Liberman. Local injection of nerve growth factor (NGF) triggers degranulation of mast cells in rat paw. *Neurosci Lett* 221, 129-132 (1997)
154. Shanas U., R. Bhasin, A. K. Sutherland, A.-J. Silverman & R. Silver. Brain mast cells lack the c-kit receptor: immunocytochemical evidence. *J Neuroimmunol* 90, 207-211 (1998)
155. Pang X., R. Letourneau, J. J. Rozniecki, L. Wang & T. C. Theoharides. Definitive characterization of rat hypothalamic mast cells. *Neuroscience* 73, 889-902 (1996)
156. Dimitriadou V., X. Pang & T. C. Theoharides. Hydroxyzine inhibits experimental allergic encephalomyelitis (EAE) and associated brain mast cell activation. *Int J Immunopharmacol* 22, 673-684 (2000)
157. Dimitriadou V., M. G. Buzzi, M. A. Moskowitz & T. C. Theoharides. Trigeminal sensory fiber stimulation induces morphologic changes reflecting secretion in rat dura mast cells. *Neuroscience* 44, 97-112 (1991)
158. Theoharides T. C., G. R. Sant, M. El-Mansoury, R. J. Letourneau, A. A. Ucci, Jr. & E. M. Meares, Jr. Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. *J Urol* 153, 629-636 (1995)
159. Letourneau R., X. Pang, G. R. Sant & T. C. Theoharides. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. *Br J Urol* 77, 41-54 (1996)
160. Dvorak A. M., R. S. McLeod, A. Onderdonk, R. A. Monahan-Earley, J. B. Cullen, D. A. Antonioli, E. Morgan, J. E. Blair, P. Estrella, R. L. Cisneros, W. Silen & Z. Cohen. Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells *in vivo*. *Int Arch Allergy Immunol* 99, 74-83 (1992)

161. Letourneau R., J. J. Rozniecki, V. Dimitriadou & T. C. Theoharides. Ultrastructural evidence of brain mast cell activation without degranulation in monkey experimental allergic encephalomyelitis. *J Neuroimmunol* 145, 18-26 (2003)
162. Kops S. K., H. Van Loveren, R. W. Rosenstein, W. Ptak & P. W. Askenase. Mast cell activation and vascular alterations in immediate hypersensitivity-like reactions induced by a T cell derived antigen-binding factor. *Lab Invest* 50, 421-434 (1984)
163. Kops S. K., T. C. Theoharides, C. T. Cronin, M. G. Kashgarian & P. W. Askenase. Ultrastructural characteristics of rat peritoneal mast cells undergoing differential release of serotonin without histamine and without degranulation. *Cell Tissue Res* 262, 415-424 (1990)
164. Theoharides T. C., P. K. Bondy, N. D. Tsakalos & P. W. Askenase. Differential release of serotonin and histamine from mast cells. *Nature* 297, 229-231 (1982)
165. Benyon R., C. Robinson & M. K. Church. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. *Br J Pharmacol* 97, 898-904 (1989)
166. Levi-Schaffer F. & M. Shalit. Differential release of histamine and prostaglandin D<sub>2</sub> in rat peritoneal mast cells activated with peptides. *Int Arch Allergy Appl Immunol* 90, 352-357 (1989)
167. van Haaster C. M., W. Engels, P. J. M. R. Lemmens, G. Hornstra, G. J. van der Vusse & J. W. M. Heemskerk. Differential release of histamine and prostaglandin D<sub>2</sub> in rat peritoneal mast cells; roles of cytosolic calcium and protein tyrosine kinases. *Biochim Biophys Acta* 1265, 79-88 (1995)
168. Leal-Berumen I., P. Conlon & J. S. Marshall. IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. *J Immunol* 152, 5468-5476 (1994)
169. Marquardt D. L., J. L. Alongi & L. L. Walker. The phosphatidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production. *J Immunol* 156, 1942-1945 (1996)
170. Gagari E., M. Tsai, C. S. Lantz, L. G. Fox & S. J. Galli. Differential release of mast cell interleukin-6 via c-kit. *Blood* 89, 2654-2663 (1997)
171. Claman H. N., K. L. Choi, W. Sujansky & A. E. Vatter. Mast cell "disappearance" in chronic murine graft-vs-host disease (GVHD)-ultrastructural demonstration of "phantom mast cells". *J Immunol* 137, 2009-2013 (1986)
172. Bugajski A. J., Z. Chiap, A. Gadek-Michalska & J. Bugajski. Effect of isolation stress on brain mast cells and brain histamine levels in rats. *Agents Actions* 41, C75-C76 (1994)
173. Silverman A. J., R. P. Millar, J. A. King, X. Zhuang & R. Silver. Mast cells containing gonadotropin-releasing hormone-like immunoreactivity in the brain of doves. *Proc Natl Acad Sci USA* 91, 3675-3699 (1994)
174. Silver R., A.-J. Silverman, L. Vitkovic & I. I. Lederhendler. Mast cells in the brain: evidence and functional significance. *Trends Neurosci* 19, 25-31 (1996)
175. Kines K. C. & H. C. Powell. Mast cell interactions with the nervous system: relationship to mechanisms of disease. *J Neuropathol Exp Neurol* 56, 627-640 (1997)
176. Bienenstock J., M. Tomioka, H. Matsuda, R. H. Stead, G. Quinonez, G. T. Simon, M. D. Coughlin & J. A. Denburg. The role of mast cells in inflammatory processes: evidence for nerve mast cell interactions. *Int Arch Allergy Appl Immunol* 82, 238-243 (1987)
177. Dimitriadou V., P. Aubineau, J. Taxi & J. Seylaz. Ultrastructural evidence for a functional unit between nerve fibers and type II cerebral mast cells in the cerebral vascular wall. *Neuroscience* 22, 621-630 (1987)
178. Newson B., A. Dahlström, L. Enerbäck & H. Ahlman. Suggestive evidence for a direct innervation of mucosal mast cells. *Neuroscience* 10, 565-570 (1983)
179. Serafin W. E. & K. F. Austen. Mediators of immediate hypersensitivity reactions. *N Engl J Med* 317, 30-34 (1987)
180. Stead R. H., M. Tomioka, G. Quinonez, G. T. Simon, S. Y. Felten & J. Bienenstock. Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. *Proc Natl Acad Sci USA* 84, 2975-2979 (1987)
181. Dvorak A. M., R. S. McLeod, A. B. Onderdonk, R. A. Monahan-Earley, J. B. Cullen, D. A. Antonioli, E. Morgan, J. E. Blair, P. Estrella, R. L. Cisneros, Z. Cohen & W. Silen. Human gut mucosal mast cells: ultrastructural observations and anatomic variation in mast cell-nerve associations *in vivo*. *Int Arch Allergy Immunol* 98, 158-168 (1992)
182. Dropp J. J. Mast cells in the mammalian brain. I. Distribution. *Acta Anat* 94, 1-21 (1976)
183. Edvinsson L., C. Owman & N. O. Sjöberg. Autonomic nerves, mast cells and amine receptors in human brain vessels. A histochemical and pharmacological study. *Brain Res* 115, 377-393 (1976)
184. Pollard H., S. Bischoff, C. Llorens-Cortes & J. C. Schwartz. Histidine decarboxylase and histamine in discrete nuclei of rat hypothalamus and the evidence for mast cells in the median eminence. *Brain Res* 118, 509-513 (1976)
185. Ibrahim M. Z. The mast cells of the mammalian central nervous system. Part I. Morphology, distribution and histochemistry. *J Neurol Sci* 21, 431-478 (1974)
186. Olsson Y. Mast cells in the nervous system. *Int Rev Cytol* 24, 27-70 (1968)
187. Goldschmidt R. C., L. B. Hough & S. D. Glick. Rat brain mast cells: contribution to brain histamine levels. *J Neurochem* 44, 1943-1947 (1985)
188. Lambrecht-Hall M., V. Dimitriadou & T. C. Theoharides. Migration of mast cells in the developing rat brain. *Dev Brain Res* 56, 151-159 (1990)
189. von Düring M., M. Bauersachs, B. Bohmer, R. W. Veh & K. H. Andres. Neuropeptide Y- and substance P-like immunoreactive nerve fibers in the rat dura mater encephali. *Anat Embryol (Berl)* 182, 363-373 (1990)
190. Powell H. C., R. S. Garrett, F. M. Brett, C.-S. Chiang, E. Chen, E. Masliah & I. L. Campbell. Response of glia, mast cells and the blood brain barrier, in transgenic mice expressing interleukin-3 in astrocytes, an experimental model for CNS demyelination. *Brain Pathol* 9, 219-235 (1999)
191. Robinson-White A. & M. A. Beaven. Presence of histamine and histamine-metabolizing enzyme in rat and guinea-pig microvascular endothelial cells. *J Pharmacol Exp Ther* 223, 440-445 (1982)
192. Kubler A., G. Rothacher, V. A. Knappertz, G. Kramer, M. Nink, J. Beyer & H. Lehnert. Intra and extracerebral

- blood flow changes and flushing after intravenous injection of human corticotropin-releasing hormone. *Clin Invest* 72, 331336-336 (1994)
193. Correa S. G., C. M. Riera, J. Spiess & I. D. Bianco. Modulation of the inflammatory response by corticotropin-releasing factor. *Eur J Pharmacol* 319, 85-90 (1997)
194. Clifton V. L., R. Crompton, R. Smith & I. M. Wright. Microvascular effects of CRH in human skin vary in relation to gender. *J Clin Endocrinol Metab* 87, 267-270 (2002)
195. Crompton R., V. L. Clifton, A. T. Bisits, M. A. Read, R. Smith & I. M. Wright. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. *J Clin Endocrinol Metab* 88, 5427-5432 (2003)
196. Kaneko K., S. Kawana, K. Arai & T. Shibasaki. Corticotropin-releasing factor receptor type 1 is involved in the stress-induced exacerbation of chronic contact dermatitis in rats. *Exp Dermatol* 12, 47-52 (2003)
197. Slominski A., J. Wortsman, T. Luger, R. Paus & S. Solomon. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. *Physiol Rev* 80, 979-1020 (2000)
198. Slominski A., B. Zbytek, A. Szczesniewski, I. Semak, J. Kaminski, T. Sweatman & J. Wortsman. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. *Am J Physiol Endocrinol Metab* 288, E701-E706 (2005)
199. Kempuraj D., N. G. Papadopoulou, M. Lytinas, M. Huang, K. Kandere-Grzybowska, B. Madhappan, W. Boucher, S. Christodoulou, A. Athanassiou & T. C. Theoharides. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. *Endocrinology* 145, 43-48 (2004)
200. Kjaer A., P. J. Larsen, U. Knigge, H. Jorgensen & J. Warberg. Neuronal histamine and expression of corticotropin-releasing hormone, vasopressin and oxytocin in the hypothalamus: relative importance of H<sub>1</sub> and H<sub>2</sub> receptors. *Eur J Endocrinol* 139, 238-243 (1998)
201. Bugajski A. J., Z. Chlap, A. Gadek-Michalska, J. Borycz & J. Bugajski. Degranulation and decrease in histamine levels of thalamic mast cells coincides with corticosterone secretion induced by compound 48/80. *Inflamm Res* 44(Supp.1), S50-S51 (1995)
202. Gadek-Michalska A., Z. Chlap, M. Turon, J. Bugajski & W. A. Fogel. The intracerebroventricularly administered mast cells degranulator compound 48/80 increases the pituitary-adrenocortical activity in rats. *Agents Actions* 32, 203-208 (1991)
203. Matsumoto I., Y. Inoue, T. Shimada & T. Aikawa. Brain mast cells act as an immune gate to the hypothalamic-pituitary-adrenal axis in dogs. *J Exp Med* 194, 71-78 (2001)
204. Mastorakos G., G. P. Chrousos & J. S. Weber. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. *J Clin Endocrinol Metab* 77, 1690-1694 (1993)
205. Navarra P., S. Tsagarakis, M. S. Faria, L. H. Rees, G. M. Besser & A. B. Grossman. Interleukins-1 and -6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus *in vitro* via the eicosanoid cyclooxygenase pathway. *Endocrinology* 128, 37-44 (1991)
206. Spinedi E., R. Hadid, T. Daneva & R. C. Gaillard. Cytokines stimulate the CRH but not the vasopressin neuronal system: evidence for a median eminence site of interleukin-6 action. *Neuroendocrinology* 56, 46-53 (1992)
207. Krüger-Krasagakes S., A. M. Möller, G. Kolde, U. Lippert, M. Weber & B. M. Henz. Production of interleukin-6 by human mast cells and basophilic cells. *J Invest Dermatol* 106, 75-79 (1996)
208. Bethin K. E., S. K. Vogt & L. J. Muglia. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. *Proc Natl Acad Sci USA* 97, 9317-9322 (2000)
209. Grabbe J., P. Welker, A. Möller, E. Dippel, L. K. Ashman & B. M. Czarnetzki. Comparative cytokine release from human monocytes, monocyte-derived immature mast cells and a human mast cell line (HMC-1). *J Invest Dermatol* 103, 504-508 (1994)
210. Angioni S., F. Petraglia, A. Gallinelli, A. Cossarizza, C. Franceschi, M. Muscettola, A. D. Genazzani, N. Surico & A. R. Genazzani. Corticotropin-releasing hormone modulates cytokines release in cultured human peripheral blood mononuclear cells. *Life Sci* 53, 1735-1742 (1993)
211. Leu S. J. & V. K. Singh. Stimulation of interleukin-6 production by corticotropin-releasing factor. *Cell Immunol* 143, 220-227 (1992)
212. Venihaki M., P. Dikkes, A. Carrigan & K. P. Karalis. Corticotropin-releasing hormone regulates IL-6 expression during inflammation. *J Clin Invest* 108, 1159-1166 (2001)
213. Ando T., J. Rivier, H. Yanaihara & A. Arimura. Peripheral corticotropin-releasing factor mediates the elevation of plasma IL-6 by immobilization stress in rats. *Am J Physiol* 275, R1461-R1467 (1998)
214. Noisakran S., W. P. Halford, L. Veress & D. J. Carr. Role of the hypothalamic pituitary adrenal axis and IL-6 in stress-induced reactivation of latent herpes simplex virus type 1. *J Immunol* 160, 5441-5447 (1998)
215. Rivest S., N. Laflamme & R. E. Nappi. Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. *J Neurosci* 15, 2680-2695 (1995)
216. Keller J. T., R. V. Dimlich, M. Zuccarello, L. Lanker, T. A. Strauss & M. J. Fritts. Influence of the sympathetic nervous system as well as trigeminal sensory fibres on rat dural mast cells. *Cephalalgia* 11, 215-221 (1991)
217. Dimitriadou V., A. Rouleau, M. D. Trung Tuong, G. J. F. Newlands, H. R. P. Miller, G. Luffau, J.-C. Schwartz & M. Garbarg. Functional relationships between sensory nerve fibers and mast cells of dura mater in normal and inflammatory conditions. *Neuroscience* 77, 829-839 (1997)
218. Cao J., N. Papadopoulou, D. Kempuraj, W. S. Boucher, K. Sugimoto, C. L. Cetrulo & T. C. Theoharides. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *J Immunol* 174, 7665-7675 (2005)
219. Cao J., C. L. Curtis & T. C. Theoharides. Corticotropin-releasing hormone (CRH) induces vascular endothelial growth factor (VEGF) release from human mast cells via the cAMP/protein kinase A/p38 MAPK pathway. *Mol Pharmacol* 69, 998-1006 (2006)

220. Papadopoulou N. G., L. Oleson, D. Kempuraj, J. Donelan, C. L. Cetrulo & T. C. Theoharides. Regulation of corticotropin-releasing hormone receptor-2 expression in human cord blood-derived cultured mast cells. *J Mol Endocrinol* 35, R1-R8 (2005)
221. Donelan J., J. Marchand, D. Kempuraj, N. Papadopoulou & T. C. Theoharides. Perifollicular and perivascular mouse skin mast cells express corticotropin-releasing hormone receptor. *J Inv Dermatol* January 26, 2006 [Epub ahead of print], (2006)
222. Paus R. & T. C. A. P. Theoharides. Neuroimmunoendocrine circuitry of the 'brain-skin connection'. *Trends Immunol* 27, 32-39 (2006)
223. Janiszewski J., J. Bienenstock & M. G. Blennerhassett. Picomolar doses of substance P trigger electrical responses in mast cells without degranulation. *Am J Physiol* 267, C138-C145 (1994)
224. Clifton V. L., M. A. Read, I. M. Leitch, W. B. Giles, A. L. A. Boura, P. J. Robinson & R. Smith. Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxide-cyclic guanosine 3',5'-monophosphate-mediated pathway. *J Clin Endocrinol Metab* 80, 2888-2893 (1995)
225. Matsushima H., N. Yamada, H. Matsue & S. Shimada. The effects of endothelin-1 on degranulation, cytokine, and growth factor production by skin-derived mast cells. *Eur J Immunol* 34, 1910-1919 (2004)
226. Szalay L., J. Kaszaki, S. Nagy & M. Boros. Endothelin-1 induces mucosal mast cell degranulation in the rat small intestine. *Life Sci* 67, 1947-1958 (2000)
227. Maurer M., J. Wedemeyer, M. Metz, A. M. Piliponsky, K. Weller, D. Chatterjea, D. E. Clouthier, M. M. Yanagisawa, M. Tsai & S. J. Galli. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. *Nature* 432, 512-516 (2004)
228. Borysenko M. & J. Borysenko. Stress, behavior, and immunity: animal models and mediating mechanisms. *Gen Hosp Psychiatry* 4, 59-67 (1982)
229. Glavin G. B., W. P. Pare, T. Sandbak, H.-K. Bakke & R. Murison. Restraint stress in biomedical research: an update. *Neurosci Biobehav Rev* 18, 223-249 (1994)
230. Williams C. L., J. M. Peterson, R. G. Villar & T. F. Burks. Corticotropin-releasing factor directly mediates colonic responses to stress. *Am J Physiol* 253, 582-586 (1987)
231. Castagliuolo I., S. E. Leeman, E. Bartolac-Suki, S. Nikulasson, B. Qiu, R. E. Carraway & C. Pothoulakis. A neurotensin antagonist, SR 48692, inhibits colonic responses to immobilization stress in rats. *Proc Natl Acad Sci USA* 93, 12611-12615 (1996)
232. Castagliuolo I., B. K. Wershil, K. Karalis, A. Pasha, S. T. Nikulasson & C. Pothoulakis. Colonic mucin release in response to immobilization stress is mast cell dependent. *Am J Physiol* 274, 1094-1100 (1998)
233. Nir I., D. Levanon & G. Iosilevsky. Permeability of blood vessels in experimental gliomas: uptake of <sup>99m</sup>Tc-glucoheptanate and alteration in blood-brain barrier as determined by cytochemistry and electron microscopy. *Neurosurgery* 25, 523-531 (1989)
234. Siegal T., R. Rubinstein, F. Bokstein, A. Schwartz, A. Lossos, E. Shalom, R. Chisin & J. M. Gomori. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. *J Neurosurg* 92, 599-605 (2000)
235. Kay A. B., G. M. Walsh, R. Moqbel, A. J. MacDonald, T. Nagakura, M. P. Carroll & H. B. Richerson. Disodium cromoglycate inhibits activation of human inflammatory cells in vitro. *J Allergy Clin Immunol* 80, 1-8 (1987)
236. Paris S. & R. Sesboue. Metastasis models: the green fluorescent revolution? *Carcinogenesis* 25, 2285-2292 (2004)
237. Logothetis L., I. A. Mylonas, S. Baloyannis, M. Pashalidou, A. Orolagas, A. Zafeiropoulos, V. Kosta & T. C. Theoharides. A pilot, open label, clinical trial using hydroxyzine in Multiple Sclerosis. *Int J Immunopathol Pharmacol* 18, 771-778 (2005)
238. Ntziachristos V., C. H. Tung, C. Bremer & R. Weissleder. Fluorescence molecular tomography resolves protease activity in vivo. *Nat Med* 8, 757-760 (2002)
239. Ntziachristos V., J. Ripoll, L. V. Wang & R. Weissleder. Looking and listening to light: the evolution of whole-body photonic imaging. *Nat Biotechnol* 23, 313-320 (2005)
240. Gurish M. F. & K. F. Austen. The diverse roles of mast cells. *J Exp Med* 194, 1-6 (2001)
241. Zappulla J. P., M. Arock, L. T. Mars & R. S. Liblau. Mast cells: new targets for multiple sclerosis therapy? *J Neuroimmunol* 131, 5-20 (2002)
242. Hendriks J. J., H. E. de Vries, S. M. van der Pol, T. K. van den Berg, E. A. van Tol & C. D. Dijkstra. Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study. *Biochem Pharmacol* 65, 877-885 (2003)
243. Aktas O., T. Prozorovski, A. Smorodchenko, N. E. Savaskan, R. Lauster, P. M. Kloetzl, C. Infante-Duarte, S. Brocke & F. Zipp. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. *J Immunol* 173, 5794-5800 (2004)
244. Middleton E., Jr., C. Kandaswami & T. C. Theoharides. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. *Pharmacol Rev* 52, 673-751 (2000)
245. Kempuraj D., B. Madhappan, S. Christodoulou, W. Boucher, J. Cao, N. Papadopoulou, C. L. Cetrulo & T. C. Theoharides. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. *Br J Pharmacol* 145, 934-944 (2005)
246. Theoharides T. C. & L. Bielory. Mast cells and mast cell mediators as targets of dietary supplements. *Ann Allergy Asthma Immunol* 93, S24-S34 (2004)
247. Theoharides T. C., M. Stein, K. Spear & S. Hauser. A pilot, double-blind, placebo-controlled clinical trial using hydroxyzine in remitting-relapsing multiple sclerosis (RR-MS). *The Pharmacologist* 44, A165 (2002)

**Abbreviations:** BBB, Blood-Brain Barrier, CRH, Corticotropin-Releasing Hormone

**Key Words:** Blood-brain-barrier, Corticotropin releasing hormone, CRH, Mast Cells, Migraines, Stress, Review

## **CRH and the blood-brain-barrier**

**Send correspondence to:** Theoharis C. Theoharides, Ph.D., M.D., Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA, Tel: 617-636-6866, Fax: 617-636-2456, E-mail: [theoharis.theoharides@tufts.edu](mailto:theoharis.theoharides@tufts.edu)

<http://www.bioscience.org/current/vol12.htm>